Literature DB >> 15509721

The effects of tamoxifen and its metabolites on platelet function and release of reactive oxygen intermediates.

Olga Vitseva1, David A Flockhart, Yan Jin, Sonia Varghese, Jane E Freedman.   

Abstract

Tamoxifen is effective in the prevention and treatment of breast cancer, but its use is associated with an increased risk of thrombosis. The mechanism for this effect is unknown. Reactive oxygen intermediates enhance platelet-dependent thrombosis, and in oncological studies, tamoxifen has been shown to increase production of reactive oxygen species. Therefore, the effects of tamoxifen and its bioactive metabolites on platelet activity and platelet reactive oxygen species were determined. Platelets were incubated with tamoxifen or the metabolites 4-hydroxy-tamoxifen (4-OH), N-desmethyl tamoxifen, or 4-hydroxy-N-desmethyl tamoxifen (endoxifen). Tamoxifen metabolites have been previously shown to possess enhanced bioactivity, and consistent with this observation, tamoxifen metabolites but not tamoxifen modestly increased platelet aggregation. These effects were similar with platelets isolated from male or female subjects. Platelet nitric oxide release or cGMP levels were not altered by incubation with tamoxifen or any of its metabolites. Incubation with tamoxifen metabolites increased stimulation-dependent platelet superoxide release [8.1 +/- 1.6 arbitrary units (a.u.) for control versus 15.2 +/- 3.5 a.u. for 4-OH; P < 0.01]. Coincubation with a superoxide dismutase mimetic eliminated the tamoxifen metabolite-induced enhancement of platelet aggregation. Corresponding to increased superoxide release, incubation with tamoxifen metabolites enhanced the functional activation of NADPH oxidase as determined by phosphorylation of its subunits p47(phox) and p67(phox). In summary, incubation of platelets with the active metabolites of tamoxifen increases stimulation-dependent superoxide release through a NADPH oxidase-dependent mechanism. This results in modest changes in platelet function and seems to be consistent with previous oncological studies demonstrating tamoxifen-dependent increase in reactive oxygen species generation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15509721     DOI: 10.1124/jpet.104.076315

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  10 in total

1.  Ribonuclease-Activated Cancer Prodrug.

Authors:  Gregory A Ellis; Nicholas A McGrath; Michael J Palte; Ronald T Raines
Journal:  ACS Med Chem Lett       Date:  2012-02-28       Impact factor: 4.345

2.  Tamoxifen Directly Inhibits Platelet Angiogenic Potential and Platelet-Mediated Metastasis.

Authors:  Kelly E Johnson; Jodi A Forward; Mason D Tippy; Julia R Ceglowski; Saleh El-Husayni; Rajesh Kulenthirarajan; Kellie R Machlus; Erica L Mayer; Joseph E Italiano; Elisabeth M Battinelli
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-02-02       Impact factor: 8.311

Review 3.  Complications and thromboembolic events associated with tamoxifen therapy in patients with breast cancer undergoing microvascular breast reconstruction: a systematic review and meta-analysis.

Authors:  Rajiv P Parikh; Elizabeth B Odom; Liyang Yu; Graham A Colditz; Terence M Myckatyn
Journal:  Breast Cancer Res Treat       Date:  2017-02-09       Impact factor: 4.872

Review 4.  Redox Mechanisms of Platelet Activation in Aging.

Authors:  Sean X Gu; Sanjana Dayal
Journal:  Antioxidants (Basel)       Date:  2022-05-19

5.  A platelet acquired storage pool disorder associated with tamoxifen therapy.

Authors:  Lalitha Nayak; Alvin H Schmaier
Journal:  Case Rep Hematol       Date:  2012-12-26

6.  Partial inhibition of estrogen-induced mammary carcinogenesis in rats by tamoxifen: balance between oxidant stress and estrogen responsiveness.

Authors:  Bhupendra Singh; Nimee K Bhat; Hari K Bhat
Journal:  PLoS One       Date:  2011-09-26       Impact factor: 3.240

7.  Effects of conjugated estrogen and bazedoxifene on hemostasis and thrombosis in mice.

Authors:  Emmanuelle Noirrit; Mélissa Buscato; Marion Dupuis; Bernard Payrastre; Coralie Fontaine; Jean-François Arnal; Marie-Cécile Valera
Journal:  Endocr Connect       Date:  2019-06       Impact factor: 3.335

Review 8.  Reactive Oxygen Species in Venous Thrombosis.

Authors:  Clemens Gutmann; Richard Siow; Adam M Gwozdz; Prakash Saha; Alberto Smith
Journal:  Int J Mol Sci       Date:  2020-03-11       Impact factor: 5.923

Review 9.  Cancer Therapy-Associated Thrombosis.

Authors:  Steven P Grover; Yohei M Hisada; Raj S Kasthuri; Brandi N Reeves; Nigel Mackman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2021-02-11       Impact factor: 8.311

Review 10.  Reprogramming of Mesothelial-Mesenchymal Transition in Chronic Peritoneal Diseases by Estrogen Receptor Modulation and TGF-β1 Inhibition.

Authors:  Robert B Wilson; Rami Archid; Marc A Reymond
Journal:  Int J Mol Sci       Date:  2020-06-10       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.